{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:33:19Z","timestamp":1773858799094,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Doctoral Development Foundation of LiHuiLi Hospital","award":["2023BSKY-LR"],"award-info":[{"award-number":["2023BSKY-LR"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05600-7","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:46:50Z","timestamp":1770882410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positive association of lipoprotein(a) and the prevalence of lower extremity arterial disease in MASLD: a cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ziliang","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meimei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinxue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ri","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"5600_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.303849","author":"MH Criqui","year":"2015","unstructured":"Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circul Res. 2015. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303849.","journal-title":"Circul Res"},{"key":"5600_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"key":"5600_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12072-023-10517-w","volume":"17","author":"MK Kang","year":"2023","unstructured":"Kang MK, Lee YR, Jang SY, Tak WY, Kweon YO, Song JE, et al. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2023;17:626\u201335. https:\/\/doi.org\/10.1007\/s12072-023-10517-w.","journal-title":"Hepatol Int"},{"key":"5600_CR4","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138\u201353. https:\/\/doi.org\/10.1136\/gutjnl-2017-313884.","journal-title":"Gut"},{"key":"5600_CR5","doi-asserted-by":"publisher","unstructured":"Denimal D, Ponnaiah M, Phan F, Jeannin A-C, Redheuil A, Salem J-E, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Cardiovasc Diabetol. 2025;24. https:\/\/doi.org\/10.1186\/s12933-025-02705-9.","DOI":"10.1186\/s12933-025-02705-9"},{"key":"5600_CR6","doi-asserted-by":"publisher","unstructured":"Zhang C, Ying Y, Ru Y, Wu Z, Tian Y, Shen P, et al. Association between FIB-4 index and lower extremity arterial disease in MASLD patients: a cross-sectional study. Lipids Health Dis. 2025;24. https:\/\/doi.org\/10.1186\/s12944-025-02516-7.","DOI":"10.1186\/s12944-025-02516-7"},{"key":"5600_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/eurjpc\/zwae271","volume":"32","author":"SL Clarke","year":"2025","unstructured":"Clarke SL, Huang RDL, Hilliard AT, Levin MG, Sharma D, Thomson B, et al. Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol. Eur J Prev Cardiol. 2025;32:116\u201327. https:\/\/doi.org\/10.1093\/eurjpc\/zwae271.","journal-title":"Eur J Prev Cardiol"},{"key":"5600_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042.","journal-title":"J Am Coll Cardiol"},{"key":"5600_CR9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","volume":"38","author":"B Gencer","year":"2017","unstructured":"Gencer B, Kronenberg F, Stroes ES, Mach F. Lipoprotein(a): the revenant. Eur Heart J. 2017;38:1553\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx033.","journal-title":"Eur Heart J"},{"key":"5600_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.10.044","author":"MD Yannick Kaiser","year":"2022","unstructured":"Yannick Kaiser MD, Marwa Daghem MD, Evangelos Tzolos MD, Mohammed N, Meah MD, Mhairi K, Doris MD, Alistair J, Moss MD, et al. Association of lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022. https:\/\/doi.org\/10.1016\/j.jacc.2021.10.044.","journal-title":"J Am Coll Cardiol"},{"key":"5600_CR11","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehq386.","journal-title":"Eur Heart J"},{"key":"5600_CR12","doi-asserted-by":"publisher","unstructured":"Zewinger S, ATHEROGENE study group., Homburg Cream and Sugar (HCS) study group, KAROLA study group, PROSPER study group, WENBIT\/WECAC study group, Mp177lipoprotein(a) and the risk of mortality in patients with established coronary heart disease: a prospective study of 116,548 patients. Nephrol Dial Transplant. 2017;32 suppl_3:iii493\u2013iii493. https:\/\/doi.org\/10.1093\/ndt\/gfx164.MP177.","DOI":"10.1093\/ndt\/gfx164.MP177"},{"key":"5600_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejim.2016.08.018","volume":"37","author":"F Fogacci","year":"2017","unstructured":"Fogacci F, Cicero AFG, D\u2019Addato S, D\u2019Agostini L, Rosticci M, Giovannini M, et al. Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella heart study. Eur J Intern Med. 2017;37:49\u201355. https:\/\/doi.org\/10.1016\/j.ejim.2016.08.018.","journal-title":"Eur J Intern Med"},{"key":"5600_CR14","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.3390\/biomedicines11123289","volume":"11","author":"AFG Cicero","year":"2023","unstructured":"Cicero AFG, Fogacci F, Giovannini M, Grandi E, D\u2019Addato S, Borghi C. Estimating the prevalence and characteristics of patients potentially eligible for lipoprotein(a)-lowering therapies in a real-world setting. Biomedicines. 2023;11:3289. https:\/\/doi.org\/10.3390\/biomedicines11123289.","journal-title":"Biomedicines"},{"key":"5600_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.11.058","author":"MD Anurag Mehta","year":"2022","unstructured":"Anurag Mehta MD, Nestor Vasquez MD, Colby R, Ayers MS, Jaideep Patel MD, Ananya Hooda M, Amit Khera MD, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol. 2022. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.058.","journal-title":"J Am Coll Cardiol"},{"key":"5600_CR16","doi-asserted-by":"publisher","first-page":"e2245720","DOI":"10.1001\/jamanetworkopen.2022.45720","volume":"5","author":"AF Gu\u00e9don","year":"2022","unstructured":"Gu\u00e9don AF, De Freminville J-B, Mirault T, Mohamedi N, Rance B, Fournier N, et al. Association of lipoprotein(a) levels with incidence of major adverse limb events. JAMA Netw Open. 2022;5:e2245720. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.45720.","journal-title":"JAMA Netw Open"},{"key":"5600_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1212\/01.wnl.0000132637.30287.b4","volume":"63","author":"JF Arenillas","year":"2004","unstructured":"Arenillas JF, Molina CA, Chac\u00f3n P, Rovira A, Montaner J, Coscojuela P, et al. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology. 2004;63:27\u201332. https:\/\/doi.org\/10.1212\/01.wnl.0000132637.30287.b4.","journal-title":"Neurology"},{"key":"5600_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1161\/STROKEAHA.122.042323","volume":"54","author":"Y Duan","year":"2023","unstructured":"Duan Y, Zhao D, Sun J, Liu J, Wang M, Hao Y, et al. Lipoprotein(a) is associated with the progression and vulnerability of new-onset carotid atherosclerotic plaque. Upd Int Car. 2023;54:1312\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.122.042323.","journal-title":"Upd Int Car"},{"key":"5600_CR19","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatology"},{"key":"5600_CR20","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","journal-title":"Hypertension"},{"key":"5600_CR21","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care. 2024;47 Suppl 1:S20\u201342. https:\/\/doi.org\/10.2337\/dc24-S002.","DOI":"10.2337\/dc24-S002"},{"key":"5600_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"5600_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40618-023-02203-3","volume":"47","author":"J He","year":"2024","unstructured":"He J, Yang M, Song C, Zhang R, Yuan S, Li J, et al. Lipoprotein(a) is associated with recurrent cardiovascular events in patients with coronary artery disease and prediabetes or diabetes. J Endocrinol Invest. 2024;47:883\u201394. https:\/\/doi.org\/10.1007\/s40618-023-02203-3.","journal-title":"J Endocrinol Invest"},{"key":"5600_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2021.11.019","volume":"349","author":"MC Verwer","year":"2022","unstructured":"Verwer MC, Waissi F, Mekke JM. High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy. Atherosclerosis. 2022;349:196\u2013203.","journal-title":"Atherosclerosis"},{"key":"5600_CR25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.jcin.2022.05.050","volume":"15","author":"Y Tomoi","year":"2022","unstructured":"Tomoi Y, Takahara M, Soga Y. Impact of high lipoprotein(a) levels on clinical outcomes following peripheral endovascular therapy. J Am Coll Cardiol Intv. 2022;15:1466\u201376.","journal-title":"J Am Coll Cardiol Intv"},{"key":"5600_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/1526602817728068","volume":"24","author":"K Hishikari","year":"2017","unstructured":"Hishikari K, Hikita H, Nakamura S. Usefulness of lipoprotein(a) for predicting clinical outcomes after endovascular therapy for aortoiliac atherosclerotic lesions. J Endovasc Ther. 2017;24:793\u20139.","journal-title":"J Endovasc Ther"},{"key":"5600_CR27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","volume":"44","author":"PE Thomas","year":"2023","unstructured":"Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur Heart J. 2023;44:1449\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehad055.","journal-title":"Eur Heart J"},{"key":"5600_CR28","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","volume":"144","author":"MH Criqui","year":"2021","unstructured":"Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American heart association. Circulation. 2021;144:e171\u201391. https:\/\/doi.org\/10.1161\/CIR.0000000000001005.","journal-title":"Circulation"},{"key":"5600_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jacc.2005.05.066","volume":"46","author":"V Aboyans","year":"2005","unstructured":"Aboyans V, Lacroix P, Postil A, Guilloux J, Roll\u00e9 F, Cornu E, et al. Subclinical peripheral arterial disease and incompressible ankle arteries are both long-term prognostic factors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol. 2005;46:815\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.066.","journal-title":"J Am Coll Cardiol"},{"key":"5600_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","volume":"349","author":"BJ Arsenault","year":"2022","unstructured":"Arsenault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. Atherosclerosis. 2022;349:7\u201316.","journal-title":"Atherosclerosis"},{"key":"5600_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","volume":"349","author":"ML Koschinsky","year":"2022","unstructured":"Koschinsky ML, Boffa MB. Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology. Atherosclerosis. 2022;349:92\u2013100.","journal-title":"Atherosclerosis"},{"key":"5600_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","volume":"349","author":"MB Boffa","year":"2022","unstructured":"Boffa MB. Beyond fibrinolysis: the confounding role of lp(a) in thrombosis. Atherosclerosis. 2022;349:72\u201381.","journal-title":"Atherosclerosis"},{"key":"5600_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa043175","volume":"353","author":"S Tsimikas","year":"2005","unstructured":"Tsimikas S, Brilakis ES, Miller ER. Oxidized phospholipids, lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46\u201357.","journal-title":"N Engl J Med"},{"key":"5600_CR34","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43:3925\u201346.","journal-title":"Eur Heart J"},{"key":"5600_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","volume":"67","author":"PR Kamstrup","year":"2021","unstructured":"Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2021;67:154\u201366.","journal-title":"Clin Chem"},{"key":"5600_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11883-025-01346-3","volume":"27","author":"T Jamialahmadi","year":"2025","unstructured":"Jamialahmadi T, Mirhadi E, Reiner \u017d, Abass KS, Almahmeed W, Virani S. Effects of Pioglitazone on lipoprotein(a): a meta-analysis. Curr Atheroscler Rep. 2025;27:94. https:\/\/doi.org\/10.1007\/s11883-025-01346-3.","journal-title":"Curr Atheroscler Rep"},{"key":"5600_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10557-017-6721-6","volume":"31","author":"G Ferretti","year":"2017","unstructured":"Ferretti G, Bacchetti T, Simental-Mend\u00eda LE, Reiner \u017d, Banach M, Sahebkar A. Raloxifene lowers plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Cardiovasc Drugs Ther. 2017;31:197\u2013208. https:\/\/doi.org\/10.1007\/s10557-017-6721-6.","journal-title":"Cardiovasc Drugs Ther"},{"key":"5600_CR38","first-page":"50","volume":"27","author":"A Sahebkar","year":"2021","unstructured":"Sahebkar A, Katsiki N, Ward N, Reiner \u017d. Flaxseed supplementation reduces plasma lipoprotein(a) levels: A meta-analysis. Altern Ther Health Med. 2021;27:50\u20133.","journal-title":"Altern Ther Health Med"},{"key":"5600_CR39","doi-asserted-by":"publisher","first-page":"8435133","DOI":"10.1155\/2022\/8435133","volume":"2022","author":"T Jamialahmadi","year":"2022","unstructured":"Jamialahmadi T, Reiner \u017d, Alidadi M, Kroh M, Almahmeed W, Ruscica M, et al. The effect of bariatric surgery on Circulating levels of lipoprotein (a): A meta-analysis. Biomed Res Int. 2022;2022:8435133. https:\/\/doi.org\/10.1155\/2022\/8435133.","journal-title":"Biomed Res Int"},{"key":"5600_CR40","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","volume":"77","author":"S Tsimikas","year":"2021","unstructured":"Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of lp(a): JACC focus seminar 2\/4. J Am Coll Cardiol. 2021;77:1576\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.051.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05600-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:38:16Z","timestamp":1773833896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05600-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5600"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05600-7","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Ningbo Medical Center LiHuiLi Hospital (Approval No. KY2024SL448-01). The requirement for informed consent was waived due to the retrospective nature of the study and the use of anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}